Personal Experience in Surgical Management of Pulmonary Pleomorphic Carcinoma

Raveglia, Federico; Mezzetti, M; Panigalli, Tiziana; Furia, Simone; Giuliani, Luigi; Conforti, Serena; Meda, Stefano

doi:10.1016/j.athoracsur.2004.04.084

Cited by 123 publications

(121 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another recent study, it was found to be 1.6% (45/2743) of resected non-small cell lung cancer (NSCLC) [8]. As in previous reports [8][9][10][11][12], most cases in our study were male with a history of smoking; they exhibited symptoms such as hemoptysis and cough.…”

Section: Discussionsupporting

confidence: 73%

“…Recurrence after surgery was frequently observed, and it should be noted that five cases with pN0 disease also relapsed. While Raveglia et al reported that nodal involvement was a determinant prognostic variable of pleomorphic carcinoma of the lung [9], Yuki et al commented that even patients with pN0 disease frequently experienced vascular invasion (57.1%) [8]. We have to keep in mind that pleomorphic carcinoma of the lung has the potential to recur even if the primary lesion is resected at an early stage.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Clinical characteristics of pleomorphic carcinoma of the lung

Ito¹,

Oizumi²,

Fukumoto³

et al. 2010

Lung Cancer

105

View full text Add to dashboard Cite

Background: Pleomorphic carcinoma of the lung is a malignant epithelial tumor that contains carcinomatous and sarcomatoid components. Due to its rarity, few studies have been reported, and its clinical and pathological characteristics remain unclear.Method: We retrospectively investigated 22 cases of pleomorphic carcinoma of the lung.Results: Fifteen cases were diagnosed by surgical resection, four by autopsy, and three by transbronchial biopsy. Nineteen patients were male and three were female, and their mean age at diagnosis was 68.3 years (± 10.1).Eighteen were current-or ex-smokers with substantial smoking histories (mean 46.4 pack-years). Sixteen patients had symptoms: hemoptysis and cough were commonly seen. Chest computed tomography (CT) findings revealed that the tumors were quite large (mean diameter 45.3 ± 21.9 mm; range 14-110 mm), and 21 tumors were peripherally located. Positron emission tomography with 18-fluorodeoxy-glucose (FDG-PET) was performed in 12 patients, and the Standardized Uptake Value (SUV) tended to be high (9.44 ± 4.98). In the 15 patients who underwent surgical resection, recurrence was common; systemic metastases were also frequently found. Patients who had received surgical 3 treatment with proper follow-up care survived longer than those who did not undergo surgery. Responses to chemotherapy were generally poor, although one patient exhibited partial response to gefitinib.Conclusions: Pulmonary pleomorphic carcinoma has strong malignant potential with frequent distant metastases, as has already been reported. However, this study demonstrated that surgical treatment and appropriate follow-up therapy might result in better prognoses.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 93%

Clinical characteristics of pleomorphic carcinoma of the lung

Ito¹,

Oizumi²,

Fukumoto³

et al. 2010

Lung Cancer

105

View full text Add to dashboard Cite

show abstract

“…As reported by Raveglia et al, the tumors in 14 patients (70%) in a group of pulmonary pleomorphic carcinoma patients consisted only of sarcomatous elements, 3 and no similarities in this regard were observed in our group of patients. As mentioned in the literature, 4,5 most pulmonary pleomorphic carcinoma patients are elderly male patients with a history of cigarette smoking.…”

Section: Discussionmentioning

confidence: 43%

Surgical treatment for pulmonary pleomorphic carcinoma: A retrospective study of 60 patients

Zhong

Fang

et al. 2014

Thoracic Cancer

View full text Add to dashboard Cite

Background: Pleomorphic carcinoma is a rare epithelial malignant tumor. Because the clinical characteristics and behavior of the disease remain unclear, we investigated the clinicopathological findings and prognosis of 60 patients with pleomorphic carcinoma. Methods: The clinicopathological characteristics of 60 cases of pulmonary pleomorphic carcinoma identified between 1999 and 2011 were studied. Of these, 55 patients had peripheral disease and five had central disease. The tumor size in all patients was 1-9.5 cm (mean, 5.8 ± 4.5 cm), while 30 had lesions with a diameter larger than 5 cm. All patients underwent pulmonary resection. Results: There were no in-hospital deaths. The three and five year survival rates of all patients were 47.2% and 25.6%, respectively. The three and five year survival rates were 57.3% and 32.5% for N0 patients, and 25.4% and 17.1% for N1-2 patients, respectively. Overall survival was significantly different between the radical resection and incomplete resection groups. Multivariate Cox regression analyses of overall survival for all 60 patients indicated that radical resection (P = 0.041), tumor node metastasis (TNM) stage (P = 0.044), and nodal status (P = 0.029) were significant independent prognostic factors. Conclusion: Pleomorphic carcinoma is a rare type of lung cancer. In our study, pleomorphic carcinoma of the lung was often found as a peripherally located large mass and was associated with a poor prognosis. Radical resection, TNM stage and nodal status were significant independent prognostic factors.

show abstract

“…Several studies have reported that pleomorphic carcinomas are associated with a more advanced stage at presentation and a poorer prognosis (1,5,8,9). Recent data indicate that pemetrexed-containing chemotherapy achieves a good response with prolonged survival in advanced conventional NSCLC (10).…”

Section: Discussionmentioning

confidence: 99%

Pemetrexed and bevacizumab-containing chemotherapy for pleomorphic carcinoma of the lung

Tamura

Ohara

Kagohashi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Pleomorphic carcinoma of the lung is a rare, highly malignant subtype of lung cancer, with a more aggressive clinical course compared with other types of non-small-cell lung cancer (NSCLC). Pemetrexed and bevacizumab are currently evaluated as two of the most reliable chemotherapeutic drugs for advanced NSCLC. We herein report a case of a 68-and a 46-year-old man with recurrent and chemo-naïve pleomorphic carcinoma of the lung, respectively, who were treated with a combination of carboplatin, pemetrexed and bevacizumab. The overall survival after the initiation of chemotherapy was 30 and 8 months, respectively. These cases exhibited a relatively long-term survival with chemotherapy. In the absence of definitive clinical trials, which are unlikely to be performed due to the rarity of this tumor, our cases demonstrated the potential utility of pemetrexed-and bevacizumab-containing chemotherapy. Our results also suggested that pemetrexed-containing chemotherapy may be key to the treatment of pleomorphic carcinoma of the lung.

show abstract

Personal Experience in Surgical Management of Pulmonary Pleomorphic Carcinoma

Cited by 123 publications

References 16 publications

Clinical characteristics of pleomorphic carcinoma of the lung

Clinical characteristics of pleomorphic carcinoma of the lung

Surgical treatment for pulmonary pleomorphic carcinoma: A retrospective study of 60 patients

Pemetrexed and bevacizumab-containing chemotherapy for pleomorphic carcinoma of the lung

Contact Info

Product

Resources

About